ViroPharma licenses Halozyme's hyaluronidase in pursuit of subcu Cinryze
This article was originally published in Scrip
Executive Summary
Under a deal potentially worth $83 million, Halozyme Therapeutics has granted the licensing rights for its recombinant human hyaluronidase enzyme (rHuPH20) technology to ViroPharma, which is using rHuPH20 to develop a subcutaneous formulation of its US FDA-approved hereditary angioedema (HAE) drug Cinryze, a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.